Keryx Biopharma (KERX) Pulls-Back After Ripping Over 160% on Zerenex DAta
Tweet Send to a FriendGet Alerts KERX Hot Sheet
Up)
Trade KERX Now!
Looks like the ride for Keryx Biopharmaceuticals Inc. (KERX) might be coming to a close.
After moving up 165 percent this week through Thursday, shares of Keryx are retracing a bit today. The stock is down over 15 percent on volume as traders look to cash out on some profits.
The move started Monday when Keryx announced Zerenex met its primary endpoint and secondary endpoint in Phase 3 trials.
Short interest through January 15th is 11.02 million shares, or 15.7 percent of float.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
After moving up 165 percent this week through Thursday, shares of Keryx are retracing a bit today. The stock is down over 15 percent on volume as traders look to cash out on some profits.
The move started Monday when Keryx announced Zerenex met its primary endpoint and secondary endpoint in Phase 3 trials.
Short interest through January 15th is 11.02 million shares, or 15.7 percent of float.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
- Cleantech Solutions (CLNT) Goes Red to Green After Yesterday's 159% Rise
- InterOil (IOC) Enters negotiations with ExxonMobil (XOM) on Development Of The Elk And Antelope Resource
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
